When patients on target-specific oral anticoagulants need surgery.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 25274657.
- Also identified by DOI 10.3949/ccjm.81a.13168.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The target-specific oral anticoagulants (TSOACs), eg, dabigatran, rivaroxaban, and apixaban, are changing the way we manage thromboembolic disease. At the same time, many clinicians wonder how best to manage TSOAC therapy when patients need surgery. An in-depth understanding of these drugs is essential to minimize the risk of bleeding and thrombosis perioperatively.
Medical subject headings
- Anticoagulants
- Blood Loss, Surgical
- Postoperative Hemorrhage
- Surgical Procedures, Operative
- Thromboembolism